Target Information
General Information of This Target
| Target ID |
TAR10008
|
|||||
|---|---|---|---|---|---|---|
| Target Name |
DNA topoisomerase 1 (TOP1)
|
|||||
| Gene Name |
TOP1
|
|||||
| Gene ID | ||||||
| Synonym |
DNA topoisomerase I
|
|||||
| Sequence |
MSGDHLHNDSQIEADFRLNDSHKHKDKHKDREHRHKEHKKEKDREKSKHSNSEHKDSEKK
HKEKEKTKHKDGSSEKHKDKHKDRDKEKRKEEKVRASGDAKIKKEKENGFSSPPQIKDEP EDDGYFVPPKEDIKPLKRPRDEDDADYKPKKIKTEDTKKEKKRKLEEEEDGKLKKPKNKD KDKKVPEPDNKKKKPKKEEEQKWKWWEEERYPEGIKWKFLEHKGPVFAPPYEPLPENVKF YYDGKVMKLSPKAEEVATFFAKMLDHEYTTKEIFRKNFFKDWRKEMTNEEKNIITNLSKC DFTQMSQYFKAQTEARKQMSKEEKLKIKEENEKLLKEYGFCIMDNHKERIANFKIEPPGL FRGRGNHPKMGMLKRRIMPEDIIINCSKDAKVPSPPPGHKWKEVRHDNKVTWLVSWTENI QGSIKYIMLNPSSRIKGEKDWQKYETARRLKKCVDKIRNQYREDWKSKEMKVRQRAVALY FIDKLALRAGNEKEEGETADTVGCCSLRVEHINLHPELDGQEYVVEFDFLGKDSIRYYNK VPVEKRVFKNLQLFMENKQPEDDLFDRLNTGILNKHLQDLMEGLTAKVFRTYNASITLQQ QLKELTAPDENIPAKILSYNRANRAVAILCNHQRAPPKTFEKSMMNLQTKIDAKKEQLAD ARRDLKSAKADAKVMKDAKTKKVVESKKKAVQRLEEQLMKLEVQATDREENKQIALGTSK LNYLDPRITVAWCKKWGVPIEKIYNKTQREKFAWAIDMADEDYEF
Click to Show/Hide
|
|||||
| 3D Structure | ||||||
| Family |
the type IB topoisomerase family
|
|||||
| Function |
Releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription by transiently cleaving and rejoining one strand of the DNA duplex. Introduces a single-strand break via transesterification at a target site in duplex DNA. The scissile phosphodiester is attacked by the catalytic tyrosine of the enzyme, resulting in the formation of a DNA-(3'-phosphotyrosyl)- enzyme intermediate and the expulsion of a 5'-OH DNA strand. The free DNA strand then rotates around the intact phosphodiester bond on the opposing strand, thus removing DNA supercoils. Finally, in the religation step, the DNA 5'-OH attacks the covalent intermediate to expel the active-site tyrosine and restore the DNA phosphodiester backbone (By similarity). Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells. Involved in the circadian transcription of the core circadian clock component BMAL1 by altering the chromatin structure around the ROR response elements (ROREs) on the BMAL1 promoter.
Click to Show/Hide
|
|||||
| Uniprot Entry | ||||||
| HGNC ID | ||||||
| KEGG ID | ||||||
Full List of The PDC Related to This Target
Phase 1
| PDC Info | PDC Name | Peptide | Receptor | Drug | Linker |
|---|---|---|---|---|---|
|
BGC-0222
|
c(RGDfK)
|
Integrin alpha-V; Integrin beta-3 (ITGAV; ITGB3)
|
Irinotecan
|
PEG114
|
Investigative
| PDC Info | PDC Name | Peptide | Receptor | Drug | Linker |
|---|---|---|---|---|---|
|
Kb-CC04
|
Kb-C04
|
Cell membrane
|
Camptothecin
|
Py-SS
|
|
|
Kb-CC03
|
Kb-C03
|
Cell membrane
|
Camptothecin
|
Py-SS
|
|
|
Kb-CC02
|
Kb-C02
|
Cell membrane
|
Camptothecin
|
Py-SS
|
|
|
SN38-HKD
|
CGVVQQ
|
Integrin alpha-V (ITGAV)
|
7-Ethyl-10-hydroxycamptothecin
|
4-(Disulfanyl)butanoic acid
|
|
|
SN38-HKD/RGDR
|
CGVVQQ
|
Integrin alpha-V (ITGAV)
|
7-Ethyl-10-hydroxycamptothecin
|
4-(Disulfanyl)butanoic acid
|
|
|
CPT-AAM-2
|
AAM-2
|
Cell membrane
|
Camptothecin
|
2-(Disulfanyl)ethyl hydrogen carbonate
|
|
|
Kb-CC01
|
Kb-C01
|
Cell membrane
|
Camptothecin
|
Py-SS
|
|
|
CPT-AAM-1
|
AAM-1
|
Cell membrane
|
Camptothecin
|
2-(Disulfanyl)ethyl hydrogen carbonate
|
|
|
HCPTMDP26-PEG
|
MDP26
|
Undisclosed
|
Hydroxycamptothecin
|
Glycylglycylglycine
|
|
|
Kb-CC05
|
Kb-C05
|
Cell membrane
|
Camptothecin
|
Py-SS
|
|
|
Kb-CC06
|
Kb-C06
|
Cell membrane
|
Camptothecin
|
Py-SS
|
|
|
Kb-CC07
|
Kb-C07
|
Cell membrane
|
Camptothecin
|
Py-SS
|
|
|
Kb-CC08
|
Kb-C08
|
Cell membrane
|
Camptothecin
|
Py-SS
|
|
|
SMAC-P1 CPT conjugates 4
|
SMAC-P1 S2
|
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Camptothecin
|
2-(Disulfanyl)ethyl hydrogen carbonate
|
|
|
SMAC-P1 CPT conjugates 5
|
SMAC-P1 S2
|
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Camptothecin
|
3-Disulfanylpropanoic Acid
|
|
|
SMAC-P1 CPT conjugates 6
|
SMAC-P1 S2
|
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Camptothecin
|
4-yl 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoate
|
|
|
SMAC-P1 CPT conjugates 1
|
SMAC-P1 S1
|
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Camptothecin
|
2-(Disulfanyl)ethyl hydrogen carbonate
|
|
|
SMAC-P1 CPT conjugates 2
|
SMAC-P1 S1
|
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Camptothecin
|
3-Disulfanylpropanoic Acid
|
|
|
SMAC-P1 CPT conjugates 3
|
SMAC-P1 S1
|
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Camptothecin
|
4-yl 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoate
|
|
|
SMAC-P1 CPT conjugates 7
|
SMAC-P1 S3
|
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Camptothecin
|
2-(Disulfanyl)ethyl hydrogen carbonate
|
|
|
SMAC-P1 CPT conjugates 8
|
SMAC-P1 S3
|
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Camptothecin
|
3-Disulfanylpropanoic Acid
|
|
|
SMAC-P1 CPT conjugates 9
|
SMAC-P1 S3
|
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Camptothecin
|
4-yl 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoate
|
|
|
ALOS4-CPT
|
ALOS4
|
Integrin alpha-V; Integrin beta-3 (ITGAV; ITGB3)
|
Camptothecin
|
GABA
|
|
|
I-4 (NPNWGRSWYNQRFKGC=(-SS-O-COO-CPT)GC=(-SS-O-COO-CPT)GRIKPRKGYTR)
|
P1GCGCGT1
|
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Camptothecin
|
2-(Disulfanyl)ethyl hydrogen carbonate
|
|
|
I-5 (NPNWGRSWYNQRFKGC=(-SS-COO-CPT)GC=(-SS-COO-CPT)GRIKPRKGYTR)
|
P1GCGCGT1
|
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Camptothecin
|
3-Disulfanylpropanoic Acid
|
|
|
I-6 (NPNWGRSWYNQRFKGC=(-S-Maleimide-CPT)GC=(-S-Maleimide-CPT)GRIKPRKGYTR)
|
P1GCGCGT1
|
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Camptothecin
|
4-yl 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoate
|
|
|
I-1 (NPNWGRSWYNQRFKGC=(-SS-O-COO-CPT)GRIKPRKGYTR)
|
P1GCGT1
|
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Camptothecin
|
2-(Disulfanyl)ethyl hydrogen carbonate
|
|
|
I-2 (NPNWGRSWYNQRFKGC=(-SS-COO-CPT)GRIKPRKGYTR)
|
P1GCGT1
|
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Camptothecin
|
3-Disulfanylpropanoic Acid
|
|
|
I-3 (NPNWGRSWYNQRFKGC=(-S-Maleimide-CPT)GRIKPRKGYTR)
|
P1GCGT1
|
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Camptothecin
|
4-yl 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoate
|
|
|
PDC-Z1
|
HER2-targeting peptide P1
|
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Camptothecin
|
Aminocaproic acid
|
|
|
PDC-Z10
|
HER2-targeting peptide P1
|
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Camptothecin
|
b-Thiosuccinimide
|
|
|
PDC-Z11
|
HER2-targeting peptide P1
|
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Camptothecin
|
Disulfide bond
|
|
|
PDC-Z12
|
HER2-targeting peptide P1
|
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Camptothecin
|
Disulfide bond
|
|
|
PDC-Z2
|
HER2-targeting peptide P1
|
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Camptothecin
|
Disulfide bond
|
|
|
PDC-Z3
|
HER2-targeting peptide P1
|
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Camptothecin
|
GFLG
|
|
|
PDC-Z4
|
HER2-targeting peptide P1
|
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Camptothecin
|
Disulfide bond
|
|
|
PDC-Z5
|
HER2-targeting peptide P1
|
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Camptothecin
|
Disulfide bond
|
|
|
PDC-Z6
|
HER2-targeting peptide P1
|
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Camptothecin
|
b-Thiosuccinimide
|
|
|
PDC-Z7
|
HER2-targeting peptide P1
|
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Camptothecin
|
Disulfide bond
|
|
|
PDC-Z8
|
HER2-targeting peptide P1
|
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Camptothecin
|
Disulfide bond
|
|
|
PDC-Z9
|
HER2-targeting peptide P1
|
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Camptothecin
|
b-Thiosuccinimide
|
|
|
Conjugates 1b
|
c(RGDfK)
|
Integrin alpha-V; Integrin beta-3 (ITGAV; ITGB3)
|
Camptothecin
|
Carbamic acid
|
|
|
Conjugates 8c
|
c(RGDfK)
|
Integrin alpha-V; Integrin beta-3 (ITGAV; ITGB3)
|
Camptothecin
|
Carbamic acid
|
|
|
PDC-CPT1
|
Cyclic peptide [W(WR)4K(βAla)]
|
Undisclosed
|
Camptothecin
|
Amide bond
|
|
|
PDC-CPT2
|
Cyclic peptide [W(WR)4K(βAla)]
|
Undisclosed
|
Camptothecin
|
3-(3-((2-(carboxyamino)ethyl)disulfaneyl)propanamido)propanoic acid
|
|
|
T7-SN-38
|
DT7
|
Transferrin receptor protein 1 (TFRC)
|
7-Ethyl-10-hydroxycamptothecin
|
Ahx-Val
|
|
|
Cot-APTEDB-SN38
|
Cot-APTEDB
|
Vesicle-associated membrane protein 8 (VAMP8)
|
7-Ethyl-10-hydroxycamptothecin
|
Ester bond
|
|
|
GSXYSCFWKTCT - Camptothecin conjugate 1
|
GSXYSCFWKTCT
|
Undisclosed
|
Camptothecin
|
Undisclosed
|
|
|
GSXYSCFWKTCT - Camptothecin conjugate 2
|
GSXYSCFWKTCT
|
Undisclosed
|
Camptothecin
|
Undisclosed
|
|
|
GSXYSCFWKTCT - Camptothecin conjugate 3
|
GSXYSCFWKTCT
|
Undisclosed
|
Camptothecin
|
Undisclosed
|
|
|
GSXYSCFWKTCT - Camptothecin conjugate 4
|
GSXYSCFWKTCT
|
Undisclosed
|
Camptothecin
|
Undisclosed
|
|
|
GSXYSCFWKTCT - Camptothecin conjugate 5
|
GSXYSCFWKTCT
|
Undisclosed
|
Camptothecin
|
Undisclosed
|
|
|
Model peptide 1 - Camptothecin conjugate
|
Model peptide 1
|
Undisclosed
|
Camptothecin
|
Triazole
|
|
|
Oligoglycin 1 - Camptothecin conjugate 1
|
Oligoglycin 1
|
Undisclosed
|
Camptothecin
|
Propyl
|
|
|
Oligoglycin 1 - Camptothecin conjugate 2
|
Oligoglycin 1
|
Undisclosed
|
Camptothecin
|
Propyl
|
|
|
Oligoglycin 2 - Camptothecin conjugate 3
|
Oligoglycin 2
|
Undisclosed
|
Camptothecin
|
Propyl
|
|
|
Oligoglycin 2 - Camptothecin conjugate 4
|
Oligoglycin 2
|
Undisclosed
|
Camptothecin
|
Propyl
|
|
|
Oligoglycin 3 - Camptothecin conjugate 5
|
Oligoglycin 3
|
Undisclosed
|
Camptothecin
|
Propyl
|
|
|
Oligoglycin 3 - Camptothecin conjugate 6
|
Oligoglycin 3
|
Undisclosed
|
Camptothecin
|
Propyl
|
|
|
Oligoglycin 4 - Camptothecin conjugate 7
|
Oligoglycin 4
|
Undisclosed
|
Camptothecin
|
Propyl
|
|
|
Oligoglycin 4 - Camptothecin conjugate 8
|
Oligoglycin 4
|
Undisclosed
|
Camptothecin
|
Propyl
|
|
|
Somatostatin backbone cyclic analog - Camptothecin conjugate
|
Somatostatin backbone cyclic analog
|
Undisclosed
|
Camptothecin
|
Butyramide
|
|
|
Tetrapeptide 53 - Camptothecin conjugate
|
Tetrapeptide 53
|
Undisclosed
|
Camptothecin
|
Propyl
|
|
|
CPT-Cyclo-GCGPep Conjugate 1
|
Cyclo-GCGPep1
|
Undisclosed
|
Camptothecin
|
2-Disulfaneylethyl hydrogen carbonate
|
|
|
CPT-Cyclo-GCGPep Conjugate 2
|
Cyclo-GCGPep1
|
Undisclosed
|
Camptothecin
|
3-Disulfaneylpropanoic acid
|
|
|
CPT-Cyclo-GCGPep Conjugate 3
|
Cyclo-GCGPep1
|
Undisclosed
|
Camptothecin
|
4-yl 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoate
|
|
|
R-L-HCPT
|
R-lycosin-I
|
Undisclosed
|
10-Hydroxycamptothecin
|
Glutaric acid
|
|
|
diCPTiRGD
|
iRGD
|
Undisclosed
|
Camptothecin
|
2-(Disulfanyl)ethyl hydrogen carbonate
|
|
|
SN38(10)-4-CDRGDK
|
CDRGDK
|
Neuropilin-1 (NRP1)
|
7-Ethyl-10-hydroxycamptothecin
|
4-(2Disulfaneylethoxy)-4-oxobutanoic acid
|
|
|
SN38(10)-4-(Ac)CDRGDK
|
CDRGDK
|
Neuropilin-1 (NRP1)
|
7-Ethyl-10-hydroxycamptothecin
|
4-(2Disulfaneylethoxy)-4-oxobutanoic acid
|
|
|
SN38(10)-(Ac)CDRGDK
|
CDRGDK
|
Neuropilin-1 (NRP1)
|
7-Ethyl-10-hydroxycamptothecin
|
3-Disulfaneylpropanoic acid
|
|
|
SN38(10)-(Ac)CGVQIRGDK
|
CGVQIRGDK
|
Neuropilin-1 (NRP1)
|
7-Ethyl-10-hydroxycamptothecin
|
3-Disulfaneylpropanoic acid
|
|
|
SN38(10)-4-(Ac)CGVQIRGDK
|
CGVQIRGDK
|
Neuropilin-1 (NRP1)
|
7-Ethyl-10-hydroxycamptothecin
|
4-(2Disulfaneylethoxy)-4-oxobutanoic acid
|
|
|
(MOM)SN38(20)-(Ac)CGVQIRGDK
|
CGVQIRGDK
|
Neuropilin-1 (NRP1)
|
7-Ethyl-10-hydroxycamptothecin
|
3-Disulfaneylpropanoic acid
|
|
|
SN38(10)-CRGDK
|
CRGDK
|
Neuropilin-1 (NRP1)
|
7-Ethyl-10-hydroxycamptothecin
|
3-Disulfaneylpropanoic acid
|
|
|
SN38(10)-4-CRGDK
|
CRGDK
|
Neuropilin-1 (NRP1)
|
7-Ethyl-10-hydroxycamptothecin
|
4-(2Disulfaneylethoxy)-4-oxobutanoic acid
|
|
|
SN38(10)-5-CRGDK
|
CRGDK
|
Neuropilin-1 (NRP1)
|
7-Ethyl-10-hydroxycamptothecin
|
5-(2-Disulfaneylethoxy)-5-oxopentanoic acid
|
|
|
SN38(10)-(Ac)CRGDK
|
CRGDK
|
Neuropilin-1 (NRP1)
|
7-Ethyl-10-hydroxycamptothecin
|
3-Disulfaneylpropanoic acid
|
|
|
SN38(10)-4-(Ac)CRGDK
|
CRGDK
|
Neuropilin-1 (NRP1)
|
7-Ethyl-10-hydroxycamptothecin
|
4-(2Disulfaneylethoxy)-4-oxobutanoic acid
|
|
|
SN38(10)-5-(Ac)CRGDK
|
CRGDK
|
Neuropilin-1 (NRP1)
|
7-Ethyl-10-hydroxycamptothecin
|
5-(2-Disulfaneylethoxy)-5-oxopentanoic acid
|
|
|
SN38(20)-4-CRGDK
|
CRGDK
|
Neuropilin-1 (NRP1)
|
7-Ethyl-10-hydroxycamptothecin
|
4-(2Disulfaneylethoxy)-4-oxobutanoic acid
|
|
|
SN38(20)-CRGDK
|
CRGDK
|
Neuropilin-1 (NRP1)
|
7-Ethyl-10-hydroxycamptothecin
|
3-Disulfaneylpropanoic acid
|
|
|
(MOM)SN38(20)-CRGDK
|
CRGDK
|
Neuropilin-1 (NRP1)
|
7-Ethyl-10-hydroxycamptothecin
|
3-Disulfaneylpropanoic acid
|
|
|
(MOM)SN38(20)-(Ac)CRGDK
|
CRGDK
|
Neuropilin-1 (NRP1)
|
7-Ethyl-10-hydroxycamptothecin
|
3-Disulfaneylpropanoic acid
|
|
|
SN38(10)-CRRGDK
|
CRRGDK
|
Neuropilin-1 (NRP1)
|
7-Ethyl-10-hydroxycamptothecin
|
3-Disulfaneylpropanoic acid
|
|
|
JF-10-81
|
Potent somatostatin analog (SSA)
|
Somatostatin receptor type 2 (SSTR2)
|
Camptothecin
|
N-carboxy-N-(2-(methylamino)ethyl)glycine
|
|
|
JF-10-71
|
Potent somatostatin analog (SSA)
|
Somatostatin receptor type 2 (SSTR2)
|
Camptothecin
|
N-(2-aminoethyl)-N-carboxyglycine
|
